Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

By |2021-05-17T18:52:30+01:00April 29th, 2021|News, Nityr|

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

By |2021-05-17T18:52:30+01:00March 15th, 2021|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

By |2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr|

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

By |2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By |2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By |2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By |2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr|

Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph

By |2021-05-17T18:52:31+01:00November 18th, 2019|News, Nityr|

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

By |2021-05-17T18:52:31+01:00October 31st, 2019|News, Nityr|

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

By |2021-05-17T18:52:31+01:00April 28th, 2019|News, Nityr|
Go to Top